Hims offers cheapest GLP-1 weight-loss pill in US in a shock to Novo, Lilly
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
TD Cowen Reiterates Hold Rating on Hims and Hers (HIMS)
February 6, 2026 6:04 AM ESTTD Cowen analyst Jonna Kim reiterated a Hold rating and $30.00 price target on Hims and Hers (NYSE: HIMS).
The analyst comments "We are hosting a Pharmacy Law Expert Call: An Update On Oral And Injectable GLP-1 Compounding today (2/6) at 12:30pm ET - please contact your sales representative if you are interested.
HIMS announced that the launch of compounded semaglutide pills starting at $49 the first month with a 5 month-plan (remaining months at $99 per month). Our take is that without this announcement, compounded GLP-1 revenue would... More
Leerink: 'there is no reason why HIMS shouldn't evaluate these launches for every subsequent weight loss product'
February 5, 2026 10:25 AM ESTLeerink Partners analyst Michael Cherny reiterated a Market Perform rating and $41.00 price target on Hims and Hers (NYSE: HIMS).
The analyst comments "Bottom Line: The compounded oral semaglutide launch announcement today is another clear example of HIMS' strategy to leverage customization and the... More
